Menu
Guest user
You are using the account as a guest user. You can also place your order directly without logging in or signing up.
- Login
- Signup
- Pharmacy
- Pharmacy Franchise
- Lab Tests
- Doctors
- Hospitals
- Blog
- For Corporate
- Home
- Pharmacy
-
Lab Tests
-
Find Specialists in City
- Dermatologist
- Gynecologist
- Neurologist
- Gastroenterologist
- Orthopedic Surgeon
- Dentist
- Ophthalmologist
- Psychiatrist
- Urologist
- Ear Nose Throat Specialist
Find Specialists in City- Cardiologist
- General Physician
- Nephrologist
- Pediatrician
- Psychologist
- Nutritionist
- Endocrinologist
- Sexologist
- Neurosurgeon
- Pulmonologist
Find Doctors by Diseases- Hyperthyroidism
- Acne Scars
- Depression
- Male Factor Infertility
- Bawaseer Piles
- Diarrhoea
- Erectile Dysfunction
- Menstruation Problems
- Eye Infection
- Sleep Disorder Insomnia
Find Doctors by Diseases- High Blood Pressure
- Heartburn
- Diabetes
- Migraine
- Kidney Stones
- Sore Throat
- Female Infertility
- Jaundice
- Skin Allergy
- Sinus Infection Sinititis
-
Hospitals of LahoreHospitals of KarachiHospitals of Islamabad
- Life Care International Hospital
- Islamabad International Hospital
- Zobia Hospital (G-9)
- MaxHealth Hospital
- Shifa International Hospital Ltd
- Ali Medical Center (Islamabad)
- Quaid-e-Azam International Hospital
- Maroof International Hospital
- Islamabad Specialist Clinic (F-8 Markaz)
- Kulsum International Hospital
Alzheimer’s Treatment; Monoclonal Antibodies Shows Potential In Mice
by Naba Batool
By and thus the overall progression of Alzheimer’s disease can be reduced.
Alzheimer’s is a neurodegenerative disease that leads to cognitive decline and results in affected memory, reasoning. Subsequently, it can also impact the basic memory such as language as well as the thinking process of a person. Every year millions of people fall prey to this disease and it is currently one of the leading causes of fatalities in the United States.
A promising new approach to potentially treat Alzheimer’s disease – and also vaccinate against it – has been developed by scientists at @uniofleicester in collaboration with University Medical Center Göttingen and @lifearc1
👉 https://t.co/WlwXpzaIEI pic.twitter.com/MYpumsCdo1
— University of Leicester (@uniofleicester) November 16, 2021
Although the quest to find the right and accurate answer to Alzheimer’s is still nowhere to be completed. But a recent collaboration between the University of Leicester in the UK and the University Medical Center Gottingen in Germany and Life Arch which is a medical charity has resulted in the production of two novel immunotherapies that can be finalized to stop the progression of this neurodegenerative disease.
Experts are firm that amyloid-beta is a protein that plays a crucial as well as causal role in the progression of Alzheimer’s. Further research has provided concrete evidence that there are certain variants of this disease that can prove to be more vital and fatal in the case of this disease.
According to Dr. Mark Carr who is the co-author of the study:
“We have identified the form of the amyloid-beta protein responsible for driving AD and have shown that specifically targeting this form of the protein in two mouse models of AD results in substantial improvements in key markers of disease progression.”
The monoclonal antibodies which are known as TAP01 can help in the treatment of this disease. On the other hand a vaccine has also been developed which will train our immune system to identify this protein and activate its defense mechanism.
